Celcuity (NASDAQ:CELC) Price Target Raised to $108.00

Celcuity (NASDAQ:CELC) had its target price boosted by Craig Hallum from $96.00 to $108.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

CELC has been the subject of several other reports. Stifel Nicolaus increased their price objective on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday. Leerink Partners upped their target price on shares of Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, July 28th. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. Finally, Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a research note on Monday, October 20th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.00.

Celcuity Stock Up 7.8%

NASDAQ CELC opened at $92.68 on Thursday. Celcuity has a 1-year low of $7.57 and a 1-year high of $94.06. The company has a market capitalization of $3.93 billion, a price-to-earnings ratio of -25.25 and a beta of 0.72. The stock’s 50 day moving average is $61.61 and its two-hundred day moving average is $36.95. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 2.24.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. The company had revenue of $0.15 million during the quarter. Equities analysts forecast that Celcuity will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Large investors have recently modified their holdings of the stock. US Bancorp DE lifted its holdings in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the period. Rhumbline Advisers grew its holdings in Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the period. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Celcuity during the 3rd quarter valued at $27,000. Intech Investment Management LLC lifted its stake in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after purchasing an additional 734 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.